GlassScriptPhysician profile
Duane M Moise
NPI 1780656439
$4,373.31
in general payments reported to CMS, 2019-2025
23 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $86.73 · 2022: $435 · 2023: $229 · 2024: $2,419 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432 · Travel and Lodging: $1,226 · Education: $69.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,431.68 |
| Travel and Lodging | $1,225.73 |
| Education | $69.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,271.36 | 2024-2025 | Interstim, Vanta Adaptivestim |
| Abbvie INC. | $434.28 | 2020-2025 | |
| Lilly USA, LLC | $397.11 | 2022-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $279.84 | 2024-2025 | Zenpep |
| Shionogi INC | $125.00 | 2019 | |
| Janssen Biotech, INC. | $101.66 | 2023-2025 | Stelara, Tremfya |
| Celgene Corporation | $89.71 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $89.07 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $79.06 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $78.14 | 2022-2024 | |
| Genzyme Corporation | $73.91 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.39 | 2024 | Eohilia, Entyvio |
| Gilead Sciences, INC. | $48.81 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $47.68 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.10 | 2024 | Cyltezo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $26.79 | 2024 | Disposable Biopsy Forceps, Single Use Electrosurgical Snare Sd-400 |
| Novo Nordisk INC | $26.07 | 2022-2023 | Rybelsus, Ozempic |
| Abbott Laboratories | $23.99 | 2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.70 | 2025 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $20.16 | 2025 | Iqirvo |
| Bayer Healthcare Pharmaceuticals INC. | $15.34 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.68 | 2023 | Quviviq |
| Ardelyx, INC. | $13.46 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duane Moise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.